NL-OMON33257已完成不适用
The effect of FOsamprenavir/Ritonavir on the pharmacokinetics of a single-dose of the antipsychotic agent olanZApine (FORZA) - FORZA
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subject is at least 18 and not older than 55 years of age at screening.
- •2. Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes in- cluded.
- •3. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- •4. Subject is in good age-appropriate health condition as established by medical his-tory, physical examination, electrocardiography, results of biochemistry, haema-tology and urinalysis testing within 4 weeks prior to the first dose. Results of bio-chemistry, haematology and urinalysis testing should be within the laboratory's reference ranges. If laboratory results are not within the reference ranges, the subject is included on condition that the Investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
- •5. Subject has a normal blood pressure and pulse rate, according to the Investiga-tor's judgement.
排除标准
- •1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
- •2. Positive HIV test.
- •3. Positive hepatitis B or C test.
- •4. Pregnant female (as confirmed by an HCG test performed less than 4 weeks be-fore the first dose) or breast-feeding female. Female subjects of childbearing po-tential without adequate contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, (double) barrier methods, or two years post-menopausal. They must agree to take precautions in order to prevent a pregnancy throughout the entire conduct of the trial.
- •5. Therapy with any drug (for two weeks preceding dosing), except for paracetamol.
- •6. Relevant history or presence of pulmonary disorders (especially COPD), cardio-vascular disorders, neurological disorders (especially seizures and migraine), gas-tro-intestinal disorders, renal and hepatic disorders, hormonal disorders (especially diabetes mellitus), coagulation disorders.
- •7. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- •8. History of or current abuse of drugs, alcohol or solvents.
- •9. Inability to understand the nature and extent of the trial and the procedures re-quired.
- •10. Participation in a drug trial within 60 days prior to the first dose.
- •11. Donation of blood within 60 days prior to the first dose.
- •12. Febrile illness within 3 days before the first dose
- •13. History of narrow-angle glaucoma
研究者
相似试验
已完成
1 期
Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)HIV InfectionsNCT00977301Radboud University Medical Center24
进行中（未招募）
不适用
An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks - Telzir/Hep C StudyAntiretroviral - Naive HIV-1 Infected Adults and Antiretroviral Experienced HIV-1 Infected AdultsMedDRA version: 9.1Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2008-001749-25-IEMater Misericordiae University Hospital160
已完成
不适用
Pilot study of simplification with fosamprenavir/ritonavir (FPV/r) monotherapyHuman immunodeficiency virus (HIV)Infections and InfestationsHuman immunodeficiency virusISRCTN78584791Institute of Biomedical Investigations of Bellvitge (Institut d'Investigació Biomèdica de Bellvitge) (IDIBELL) (Spain)30
招募中
不适用
Comparison of the effects of sevoflurane and remimazolam anesthesia on regional cerebral oxygen saturation and optic nerve sheath diameter in patients undergoing laparoscopic gynecological surgeryKCT0006900Gachon University Gil Medical Center62
招募中
不适用
The interaction of Antiretroviral Drugs with the MicrobiomeCirculatory SystemHIV/AIDSNutritional, Metabolic, EndocrinePACTR202108587192356WS300